Bharat Biotech to launch intranasal Coronavirus vaccine ‘iNCOVACC’ on Republic Day
Bharat Biotech will launch its intranasal COVID-19 vaccine ‘iNCOVACC‘ on January 26, the company’s CMD Krishna Ella announced here on Saturday. The nasal vaccine can be taken after six months of the second dose.
Central Drugs Standard Control Organization (CDSCO) has already given approval to the vaccine manufacturer earlier this month for the nasal vaccine, the first of its kind in India.
“Our nasal vaccine will be officially launched on Republic Day on January 26,” said Ella while participating in a session during the 8th edition of the India International Science Festival (IISF) that began at the Maulana Azad National Institute of Technology (MANIT), here on Saturday.
The session was titled ‘Face-to-Face with New Frontiers in Science‘. The company had earlier announced that it would price the intranasal vaccine at Rs.325 per shot for procurement by the government, and Rs.800 per shot for private vaccination centres.
As per the vaccine manufacturer, the nasal route has excellent potential for vaccination due to the organized immune system of the nasal mucosa. Thus, intranasal immunization of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus, thereby protecting against disease, infection, and transmission.
[With Inputs from IANS]
PGurus is now on Telegram. Click here to join our channel and stay updated with all the latest news and views
For all the latest updates, download PGurus App.
- PM Modi calls on countries to invest in resilient infrastructure at 39-nation meet on natural disasters - April 24, 2024
- Elon Musk’s X to launch dedicated TV app for videos soon - April 24, 2024
- ‘Made in India’: DRDO develops lightest bulletproof jacket for protection against highest threat level - April 24, 2024
India got to be proud.